Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.
Sousa BB, de Almeida CR, Barahona AF, Lopes R, Martins-Logrado A, Cavaco M, Neves V, Carvalho LAR, Labão-Almeida C, Coelho AR, Leal Bento M, Lopes RMRM, Oliveira BL, Castanho MARB, Neumeister P, Deutsch A, Vladimer GI, Krall N, João C, Corzana F, Seixas JD, Fior R, Bernardes GJL.
Sousa BB, et al. Among authors: oliveira bl.
ACS Pharmacol Transl Sci. 2022 Nov 2;5(11):1156-1168. doi: 10.1021/acsptsci.2c00163. eCollection 2022 Nov 11.
ACS Pharmacol Transl Sci. 2022.
PMID: 36407952
Free PMC article.